Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 216

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials

Zaccara, Gaetano, Gangemi, Pierfranco, Perucca, Piero, Specchio, Luigi · 2011 · Epilepsia

Abstract

Summary: Purpose: Despite the widespread use of antiepileptic drugs (AEDs) across different neurologic and psychiatric disorders, no study has systematically reviewed all available randomized controlled trials (RCTs) of a given AED to fully uncover its tolerability profile. We aimed at identifying treatment emergent adverse events (AEs) associated with pregabalin through a systematic review and meta‐analysis of all available RCTs. We also assessed the association between serious AEs and pregabalin, and investigated whether pregabalin AEs display a dose–response relationship. Methods: We searched MEDLINE, EMBASE, and Cochrane CENTRAL to February 2010 for RCTs. Additional studies were identified from reference lists of retrieved papers and from online clinical databases. We selected placebo‐controlled, double‐blind RCTs investigating the therapeutic effects of pregabalin in adults with any condition. Studies had to include at least 20 subjects per arm and have a duration of at least 4 weeks. AEs were assessed for their association with pregabalin after identification/exclusion of synonyms, rare AEs, and nonassessable AEs due to methodologic limitations. We used relative risks (RRs) to assess the association of any [99% confidence intervals (CIs)] or serious AEs (95% CIs) with pregabalin, and risk differences (RDs, 95% CIs) to investigate dose–response relationships of pregabalin AEs. Key findings: Thirty‐eight RCTs were included in our study. Of 39 AEs, 20 (51%) were significantly associated with pregabalin (dizziness, vertigo, incoordination, balance disorder, ataxia, diplopia, blurred vision, amblyopia, tremor, somnolence, confusional state, disturbance in attention, thinking abnormal, euphoria, asthenia, fatigue, edema, peripheral edema, dry mouth, constipation). The highest RRs were found for cognition/coordination AEs. There was no significant association between serious AEs and pregabalin. There was a selective dose–response pattern in the onset of pregabalin AEs, with certain AEs appearing at lower doses than others. Significance: Individuals starting treatment with pregabalin are at increased risk for several AEs, particularly those affecting cognition/coordination. Pregabalin AEs appear according to a selective dose–response pattern, possibly reflecting the severity of dysfunction of distinct anatomic structures. These findings may aid clinicians in providing better patient management, and support the value of including in meta‐analyses of AED tolerability profiles RCTs performed in different conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1528-1167.2010.02966.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 57

  1. 10.1186/1471-2377-8-33 · DOI · Paper page
  2. 10.1111/j.1526-4637.2007.00332.x · DOI
  3. 10.1111/j.0013-9580.2004.31203.x · doi:10.1111/j.0013-9580.2004.31203.x
  4. 10.1111/j.0013-9580.2004.455003.x · DOI · Paper page
  5. 10.1212/01.WNL.0000150932.48688.BE · doi:10.1212/01.wnl.0000150932.48688.be
  6. Chadwick DW, 2000, Zonisamide for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 2
  7. Chadwick DW, 2002, Zonisamide add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 4, CD001416
  8. Chadwick DW, 2005, Zonisamide add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 4, CD001416
  9. Chaisewikul R, 2001, Levetiracetam add‐on for drug‐resistant localization related (partial) epilepsy, Cochrane Database Syst Rev, 1, CD001901
  10. 10.1002/art.20983 · DOI · Paper page
  11. de Haas S, 2007, Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy, J Clin Sleep Med, 3, 473, 10.5664/jcsm.26911 · DOI
  12. 10.1212/01.WNL.0000055433.55136.55 · DOI · Paper page
  13. 10.1111/j.1528-1167.2005.00341.x · doi:10.1111/j.1528-1167.2005.00341.x
  14. 10.1097/01.jcp.0000084032.22282.ff · DOI · Paper page
  15. 10.1097/YIC.0b013e3282f0f0d7 · DOI
  16. 10.1016/j.jns.2009.06.044 · DOI
  17. 10.1212/01.WNL.0000068024.20285.65 · DOI · Paper page
  18. 10.1016/j.pain.2005.02.032 · DOI · Paper page
  19. Hemming K, 2008, Vigabatrin for refractory partial epilepsy, Cochrane Database Syst Rev, 3, CD007302
  20. 10.1136/gut.2006.110858 · DOI · Paper page
  21. Jette NJ, 2000, Topiramate for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 2, CD001417
  22. Jette NJ, 2002, Topiramate add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 3, CD001417
  23. Jette N, 2008, Topiramate add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 3, CD001417
  24. 10.1097/YIC.0b013e32831d7980 · DOI
  25. Leach JP, 2002, Remacemide for drug‐resistant localization related epilepsy, Cochrane Database Syst Rev, 4, CD001900
  26. 10.1111/j.1528-1167.2008.01954.x · doi:10.1111/j.1528-1167.2008.01954.x
  27. 10.1212/01.WNL.0000145767.36287.A1 · DOI · Paper page
  28. 10.1073/pnas.0710771105 · DOI
  29. Lozsadi D, 2008, Pregabalin add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 1, CD005612
  30. 10.1111/j.1528-1157.1997.tb01251.x · DOI · Paper page
  31. Marson AG, 2000, Gabapentin for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 2, CD001415
  32. 10.1016/S0920-1211(01)00287-X · DOI
  33. Mease PJ, 2008, A randomized, double‐blind, placebo‐controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia, J Rheumatol, 35, 502
  34. Michael B, 2008, Clobazam as an add‐on in the management of refractory epilepsy, Cochrane Database Syst Rev, 2, CD004154
  35. 10.4088/JCP.v67n0511 · DOI · Paper page
  36. 10.1192/bjp.bp.107.037788 · DOI
  37. 10.1016/j.bbr.2009.11.042 · DOI
  38. 10.1176/appi.ajp.160.3.533 · DOI · Paper page
  39. Pereira J, 2002, Tiagabine add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 3, CD001908
  40. 10.1212/01.wnl.0000345667.45642.61 · DOI · Paper page
  41. 10.1097/01.jcp.0000155820.74832.b0 · DOI · Paper page
  42. Ramaratnam S, 2000, Lamotrigine add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 3
  43. RevMan, 2008, Review Manager (RevMan) [Computer program]. Version 5.0
  44. 10.1016/j.jpain.2004.12.007 · DOI · Paper page
  45. 10.1001/archpsyc.62.9.1022 · DOI · Paper page
  46. 10.1017/S1092852900015571 · DOI
  47. 10.1016/j.pain.2004.05.001 · DOI · Paper page
  48. 10.2147/NDT.S4716 · doi:10.2147/ndt.s4716
  49. 10.1111/j.1468-1331.2009.02916.x · DOI
  50. 10.1016/j.pain.2004.01.001 · DOI · Paper page
  51. 10.1212/01.wnl.0000244422.45278.ff · DOI · Paper page
  52. 10.1016/j.jpain.2008.05.014 · DOI
  53. 10.1016/j.ejpain.2007.05.003 · DOI · Paper page
  54. 10.1185/030079906X80404 · DOI · Paper page
  55. 10.1016/j.pain.2007.06.033 · DOI · Paper page
  56. Zesiewicz TA, 2007, A pilot, double‐blind, placebo‐controlled trial of pregabalin (Lyrica) in the treatment of essential tremor, Mov Disord, 22, 1661
  57. 10.1038/ng0197-62 · DOI · Paper page

Cited by

See all 216

Metadata

Authors
Zaccara, G., Gangemi, P., Perucca, P., & Specchio, L.
Venue
Epilepsia
Publisher
Wiley
Published
2011-02-14
Volume
52
Issue
4
Pages
826-836
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W1965579959
Cited by
216
References
4
FWCI
3.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1111/j.1528-1167.2010.02966.x
The paper
Zaccara, G., Gangemi, P., Perucca, P., & Specchio, L. (2011). The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials. Epilepsia. https://doi.org/10.1111/j.1528-1167.2010.02966.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.